Abstract
Obesity or overweight is a risk factor for several health disorders such as type 2 diabetes, hypertension, and certain cancers. Furthermore, obesity affects almost all body systems including the extracellular matrix (ECM) by generating a pro-inflammatory environment, which are associated with abnormal secretions of several cytokines or hormonal substances, for example, insulin-like growth factors (IGFs), leptin, and sex hormones. These chemical mediators most likely have a great impact on the ECM. Accumulating evidence suggests that both obesity and ECM can influence tumor growth and progression through a number of chemical mediators. Conversely, cells in the connective tissue, namely fibroblasts and macrophages, support and aggravate the inflammatory situation in obesity by releasing several cytokines or growth factors such as vascular endothelial growth factor, epidermal growth factor, and transforming growth factor-beta (TGF-β). A wide range of functions are performed by TGF-β in normal health and pathological conditions including tumorigenesis. Breast cancer in postmenopausal women is a classic example of obesity-related cancer wherein several of these conditions, for example, higher levels of pro-inflammatory cytokines, impairment in the regulation of estrogen and growth factors, and dysregulation of different ECM components may favor the neoplastic process. Aberrant expressions of ECM components such as matrix metalloproteinases or matricellular proteins in both obesity and cancer have been reported by many studies. Nonstructural matricellular proteins, viz., thrombospondins, secreted protein acidic and rich in cysteine (SPARC), and Cyr61-CTGF-Nov (CCN), which function as modulators of cell-ECM interactions, exhibit protean behavior in cancer. Precise understanding of ECM biology can provide potential therapeutic targets to combat obesity-related pathologies.
Acknowledgments
We are thankful to Dr Claude-Bernard lliou, Professor and Dean, Saint James School of Medicine, Anguilla, for his constant support.
Conflict of financial and/or other interest: None
References
1. Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, Zhang Y, Uemura M, Osako A, Ozaki Y, Aoyama A. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 2014;78:2807–18.10.1253/circj.CJ-14-0850Search in Google Scholar PubMed
2. González Svatetz CA, GodayArnó A. Obesity and cancer: dangerous friendship. Med Clin (Barc) (Online 2014 Jul 11; PubMed ID: 25023851; doi: 10.1016/j.medcli.2014.05.026).Search in Google Scholar
3. Ray A, Barreto SC, Armstrong E, Dogan S. Pathobiology of cancer and clinical biochemistry. J Pediatr Biochem 2013;3:187–201.10.1055/s-0036-1586447Search in Google Scholar
4. Sánchez RC, Ibáñez C, Klaassen J. The link between obesity and cancer. Rev Med Chil 2014;142:211–21.10.4067/S0034-98872014000200010Search in Google Scholar
5. Ungefroren H, Gieseler F, Lehnert H. Obesity and cancer. Internist (Berl) 2015;56:127–36.10.1007/s00108-014-3536-4Search in Google Scholar PubMed
6. Stivarou T, Patsavoudi E. Extracellular molecules involved in cancer cell invasion. Cancers (Basel) 2015;7:238–65.10.3390/cancers7010238Search in Google Scholar PubMed PubMed Central
7. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 2014;15:1243–53.10.15252/embr.201439246Search in Google Scholar PubMed PubMed Central
8. Ding L, Zhao Y, Warren CL, Sullivan R, Eliceiri KW, Shull JD. Association of cellular and molecular responses in the rat mammary gland to 17β-estradiol with susceptibility to mammary cancer. BMC Cancer 2013;13:573.10.1186/1471-2407-13-573Search in Google Scholar PubMed PubMed Central
9. Markiewicz M, Znoyko S, Stawski L, Ghatnekar A, Gilkeson G, Trojanowska M. A role for estrogen receptor-α and estrogen receptor-β in collagen biosynthesis in mouse skin. J Invest Dermatol 2013;133:120–7.10.1038/jid.2012.264Search in Google Scholar PubMed PubMed Central
10. Roy D, Calaf GM. Mutation of β-catenin in a radiation and estrogen breast cancer model. Int J Oncol 2015;46:153–60.10.3892/ijo.2014.2722Search in Google Scholar PubMed
11. Jain R, Strickler HD, Fine E, Sparano JA. Clinical studies examining the impact of obesity on breast cancer risk and prognosis. J Mammary Gland Biol Neoplasia 2013;18:257–66.10.1007/s10911-013-9307-3Search in Google Scholar PubMed
12. Valladares M, Corsini G, Romero C. Association between obesity and ovarian cancer. Rev Med Chil 2014;142:593–8.10.4067/S0034-98872014000500007Search in Google Scholar PubMed
13. Ali AT. Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 2014;24:384–93.10.1097/IGC.0000000000000075Search in Google Scholar PubMed
14. Meides A, Gutschalk CM, Devel L, Beau F, Czarny B, Hensler S, Neugebauer J, Dive V, Angel P, Mueller MM. Effects of selective MMP-13 inhibition in squamous cell carcinoma depend on estrogen. Int J Cancer 2014;135:2749–59.10.1002/ijc.28866Search in Google Scholar PubMed
15. Dang Y, Li W, Tran V, Khalil RA. EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochem Pharmacol 2013;86:734–47.10.1016/j.bcp.2013.06.030Search in Google Scholar PubMed PubMed Central
16. Russo LA, Peano BJ, Trivedi SP, Cavalcanto TD, Olenchock BA, Caruso JA, Smolock AR, Vishnevsky O, Gardner RM. Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus. Reprod Biol Endocrinol 2009;7:124.10.1186/1477-7827-7-124Search in Google Scholar PubMed PubMed Central
17. Nilsson UW, Garvin S, Dabrosin C. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 2007;102:253–61.10.1007/s10549-006-9335-4Search in Google Scholar PubMed
18. KousidouOCh, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, Karamanos NK. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2008;2:223–32.10.1016/j.molonc.2008.06.002Search in Google Scholar PubMed PubMed Central
19. Leśniewska M, Miltyk W, Swiatecka J, Tomaszewska M, Kuźmicki M, Pałka J, Wołczyński S. Estrogen receptor beta participate in the regulation of metabolizm of extracellular matrix in estrogen alpha negative breast cancer. Folia Histochem Cytobiol 2009;47:S107–12.10.2478/v10042-009-0047-6Search in Google Scholar PubMed
20. Sisci D, Middea E, Morelli C, Lanzino M, Aquila S, Rizza P, Catalano S, Casaburi I, Maggiolini M, Andò S. 17β-estradiol enhances α(5) integrin subunit gene expression through ERα-Sp1 interaction and reduces cell motility and invasion of ERα-positive breast cancer cells. Breast Cancer Res Treat 2010;124:63–77.10.1007/s10549-009-0713-6Search in Google Scholar PubMed
21. Lindberg K, Ström A, Lock JG, Gustafsson JA, Haldosén LA, Helguero LA. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 2010;222:156–67.10.1002/jcp.21932Search in Google Scholar PubMed
22. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007;8:215.10.1186/gb-2007-8-5-215Search in Google Scholar PubMed PubMed Central
23. Soldano S, Montagna P, Brizzolara R, Sulli A, Parodi A, Seriolo B, Paolino S, Villaggio B, Cutolo M. Effects of estrogens on extracellular matrix synthesis in cultures of human normal and scleroderma skin fibroblasts. Ann N Y Acad Sci 2010;1193:25–9.10.1111/j.1749-6632.2009.05296.xSearch in Google Scholar PubMed
24. Hyder SM, Liang Y, Wu J. Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int J Cancer 2009;125:1045–53.10.1002/ijc.24373Search in Google Scholar PubMed PubMed Central
25. Tan O, Ornek T, Seval Y, Sati L, Arici A. Tenascin is highly expressed in endometriosis and its expression is upregulated by estrogen. Fertil Steril 2008;89:1082–9.10.1016/j.fertnstert.2007.05.028Search in Google Scholar PubMed
26. Kashyap AS, Hollier BG, Manton KJ, Satyamoorthy K, Leavesley DI, Upton Z. Insulin-like growth factor-I:vitronectin complex-induced changes in gene expression effect breast cell survival and migration. Endocrinology 2011;152:1388–401.10.1210/en.2010-0897Search in Google Scholar PubMed
27. Canonici A, Steelant W, Rigot V, Khomitch-Baud A, Boutaghou-Cherid H, Bruyneel E, Van Roy F, Garrouste F, Pommier G, André F. Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int J Cancer 2008;122:572–82.10.1002/ijc.23164Search in Google Scholar PubMed
28. Fujita M, Ieguchi K, Cedano-Prieto DM, Fong A, Wilkerson C, Chen JQ, Wu M, Lo SH, Cheung AT, Wilson MD, Cardiff RD, Borowsky AD, Takada YK, Takada Y. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R. J Biol Chem 2013;288:19593–603.10.1074/jbc.M113.470872Search in Google Scholar PubMed PubMed Central
29. Bartlett RS, Heckman WW, Isenberg J, Thibeault SL, Dailey SH. Genetic characterization of vocal fold lesions: leukoplakia and carcinoma. Laryngoscope 2012;122:336–42.10.1002/lary.22417Search in Google Scholar PubMed PubMed Central
30. Wells A, Chao YL, Grahovac J, Wu Q, Lauffenburger DA. Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) 2011;16:815–37.10.2741/3722Search in Google Scholar PubMed PubMed Central
31. Mira E, Mañes S, Lacalle RA, Márquez G, Martínez-A C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999;140:1657–64.10.1210/endo.140.4.6623Search in Google Scholar PubMed
32. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974–82.10.1038/sj.onc.1206197Search in Google Scholar PubMed
33. Ozbay T, Nahta R. A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Mol Cancer Res 2008;6:1052–8.10.1158/1541-7786.MCR-07-2126Search in Google Scholar PubMed PubMed Central
34. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O’Regan RM, Sharma D. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008;68:9712–22.10.1158/0008-5472.CAN-08-1952Search in Google Scholar PubMed PubMed Central
35. McMurtry V, Simeone AM, Nieves-Alicea R, Tari AM. Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells. Clin Exp Metastasis 2009;26:197–204.10.1007/s10585-008-9231-xSearch in Google Scholar PubMed
36. Wang L, Cao H, Pang X, Li K, Dang W, Tang H, Chen T. The effect of leptin and its mechanisms on the migration and invasion of human breast cancer MCF-7 cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (Chinese Journal of Cellular and Molecular Immunology) 2013;29:1272–6.Search in Google Scholar
37. Dong Z, Xu X, Du L, Yang Y, Cheng H, Zhang X, Li Z, Wang L, Li J, Liu H, Qu X, Wang C. Leptin-mediated regulation of MT1-MMP localization is KIF1B dependent and enhances gastric cancer cell invasion. Carcinogenesis 2013;34:974–83.10.1093/carcin/bgt028Search in Google Scholar PubMed
38. Perera CN, Chin HG, Duru N, Camarillo IG. Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. J Endocrinol 2008;199:221–33.10.1677/JOE-08-0215Search in Google Scholar PubMed
39. Majumdar P, Chen S, George B, Sen S, Karmazyn M, Chakrabarti S. Leptin and endothelin-1 mediated increased extracellular matrix protein production and cardiomyocyte hypertrophy in diabetic heart disease. Diabetes Metab Res Rev 2009;25:452–63.10.1002/dmrr.964Search in Google Scholar PubMed
40. Dong Z, Fu S, Xu X, Yang Y, Du L, Li W, Kan S, Li Z, Zhang X, Wang L, Li J, Liu H, Qu X, Wang C. Leptin-mediated regulation of ICAM-1 is Rho/ROCK dependent and enhances gastric cancer cell migration. Br J Cancer 2014;110:1801–10.10.1038/bjc.2014.70Search in Google Scholar PubMed PubMed Central
41. Dadson K, Chasiotis H, Wannaiampikul S, Tungtrongchitr R, Xu A, Sweeney G. Adiponectin mediated APPL1-AMPK signaling induces cell migration, MMP activation, and collagen remodeling in cardiac fibroblasts. J Cell Biochem 2014;115:785–93.10.1002/jcb.24722Search in Google Scholar PubMed
42. Ezure T, Amano S. Negative regulation of dermal fibroblasts by enlarged adipocytes through release of free fatty acids. J Invest Dermatol 2011;131:2004–9.10.1038/jid.2011.145Search in Google Scholar PubMed
43. Vuohelainen S, Pirinen E, Cerrada-Gimenez M, Keinänen TA, Uimari A, Pietilä M, Khomutov AR, Jänne J, Alhonen L. Spermidine is indispensable in differentiation of 3T3-L1 fibroblasts to adipocytes. J Cell Mol Med 2010;14:1683–92.10.1111/j.1582-4934.2009.00808.xSearch in Google Scholar PubMed PubMed Central
44. Zhu J, Pang D, Zhou Y, Tang X, Huang Y, Xie W, Gao F, Lai L, Zhang M, Ouyang H. Direct conversion of porcine embryonic fibroblasts into adipocytes by chemical molecules. Cell Reprogram 2012;14:99–105.10.1089/cell.2011.0074Search in Google Scholar PubMed
45. Criscitiello C, Esposito A, Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. Curr Opin Oncol 2014;26:551–5.10.1097/CCO.0000000000000122Search in Google Scholar PubMed
46. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012;23:83–9.10.1016/j.tem.2011.10.003Search in Google Scholar PubMed PubMed Central
47. Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K, Wang J. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene (Online 2014 Jun 9; PubMed ID: 24909173; doi: 10.1038/onc.2014.158) (Comment: Oncogene 2014;33:4450).10.1038/onc.2014.224Search in Google Scholar
48. Chiarugi P, Paoli P, Cirri P. Tumor microenvironment and metabolism in prostate cancer. Semin Oncol 2014;41:267–80.10.1053/j.seminoncol.2014.03.004Search in Google Scholar PubMed
49. De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K. Cancer associated fibroblasts and tumor growth: focus on multiple myeloma. Cancers (Basel) 2014;6:1363–81.10.3390/cancers6031363Search in Google Scholar PubMed PubMed Central
50. Talar B, Czyż M. TGF-β signaling pathways in cancers. Postepy Hig Med Dosw (Online) 2013;67:1008–17.10.5604/17322693.1068073Search in Google Scholar PubMed
51. Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-β function. J Biochem 2012;152:321–9.10.1093/jb/mvs089Search in Google Scholar PubMed PubMed Central
52. Pereira S, Teixeira L, Aguilar E, Oliveira M, Savassi-Rocha A, Pelaez JN, Capettini L, Diniz MT, Ferreira A, Alvarez-Leite J. Modulation of adipose tissue inflammation by FOXP3+ Treg cells, IL-10, and TGF-β in metabolically healthy class III obese individuals. Nutrition 2014;30:784–90.10.1016/j.nut.2013.11.023Search in Google Scholar PubMed
53. Ali AT, Hochfeld WE, Myburgh R, Pepper MS. Adipocyte and adipogenesis. Eur J Cell Biol 2013;92:229–36.10.1016/j.ejcb.2013.06.001Search in Google Scholar PubMed
54. Wang YC, Li Y, Wang XY, Zhang D, Zhang H, Wu Q, He YQ, Wang JY, Zhang L, Xia H, Yan J, Li X, Ying H. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia 2013;56:2275–85.10.1007/s00125-013-2996-8Search in Google Scholar PubMed
55. Semenchenko IIu, Sharafetdinov KhKh, Plotnikova OA, Alekseeva RI, Sentsova TB, Vorozhko IV. Markers of immune inflammation in patients with type 2 diabetes and obesity. Vopr Pitan 2013;82:46–50.Search in Google Scholar
56. Vinagre I, Sánchez-Quesada JL, Sánchez-Hernández J, Santos D, Ordoñez-Llanos J, De Leiva A, Pérez A. Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc Diabetol 2014;13:34.10.1186/1475-2840-13-34Search in Google Scholar PubMed PubMed Central
57. Otranto M, Nascimento AP, Monte-Alto-Costa A. Insulin resistance impairs cutaneous wound healing in mice. Wound Repair Regen 2013;21:464–72.10.1111/wrr.12042Search in Google Scholar PubMed
58. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010;21:49–59.10.1016/j.cytogfr.2009.11.008Search in Google Scholar PubMed PubMed Central
59. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013;33(Suppl 1):S79–84.10.1007/s10875-012-9847-0Search in Google Scholar PubMed
60. Sun X, Ingman WV. Cytokine networks that mediate epithelial cell-macrophage crosstalk in the mammary gland: implications for development and cancer. J Mammary Gland Biol Neoplasia 2014;19:191–201.10.1007/s10911-014-9319-7Search in Google Scholar PubMed
61. Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Role of extracellular matrix remodelling in adipose tissue pathophysiology: relevance in the development of obesity. Histol Histopathol 2012;27:1515–28.Search in Google Scholar
62. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity 2014;41:36–48.10.1016/j.immuni.2014.05.010Search in Google Scholar PubMed
63. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 2010;88:33–9.10.1189/jlb.0210072Search in Google Scholar PubMed
64. Murthy NS, Mukherjee S, Ray G, Ray A. Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med 2009;55:45–54.10.4103/0022-3859.43549Search in Google Scholar PubMed
65. Iskander K, Farhour R, Ficek M, Ray A. Obesity-related complications: few biochemical phenomena with reference to tumorigenesis. Malays J Pathol 2013;35:1–15.Search in Google Scholar
66. Joost HG. Diabetes and cancer: epidemiology and potential mechanisms. Diab Vasc Dis Res 2014;11:390–4.10.1177/1479164114550813Search in Google Scholar PubMed
67. Dean SJ, Rhodes A. Triple negative breast cancer: the role of metabolic pathways. Malays J Pathol 2014;36:155–62.Search in Google Scholar
68. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE Jr, Peterson CA, Kern PA. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab 2011;96:E1990–8.10.1210/jc.2011-1567Search in Google Scholar PubMed PubMed Central
69. Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem 2012;60:976–86.10.1369/0022155412465073Search in Google Scholar PubMed PubMed Central
70. Marini G, Rinaldi Jde C, Damasceno DC, Felisbino SL, Rudge MV. Changes in the extracellular matrix due to diabetes and their impact on urinary continence. Rev Bras Ginecol Obstet 2014;36:328–33.10.1590/SO100-720320140005014Search in Google Scholar PubMed
71. Berg G, Schreier L, Miksztowicz V. Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects. Horm Mol Biol Clin Investig 2014;17:79–87.10.1515/hmbci-2013-0069Search in Google Scholar PubMed
72. Minematsu T, Huang L, Ibuki A, Nakagami G, Akase T, Sugama J, Nagase T, Yoshimura K, Sanada H. Altered expression of matrix metalloproteinases and their tissue inhibitors in matured rat adipocytes in vitro. Biol Res Nurs 2012;14:242–9.10.1177/1099800411410870Search in Google Scholar PubMed
73. Hopps E, Caimi G. Matrix metalloproteinases in metabolic syndrome. Eur J Intern Med 2012;23:99–104.10.1016/j.ejim.2011.09.012Search in Google Scholar PubMed
74. Derosa G, Ferrari I, D’Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008;15:219–24.10.1080/10623320802228815Search in Google Scholar PubMed
75. Papazoglou D, Papatheodorou K, Papanas N, Papadopoulos T, Gioka T, Kabouromiti G, Kotsiou S, Maltezos E. Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss? Exp Clin Endocrinol Diabetes 2010;118:730–4.10.1055/s-0030-1249671Search in Google Scholar PubMed
76. Ray A, Cleary MP. Obesity and breast cancer: a clinical biochemistry perspective. Clin Biochem 2012;45:189–97.10.1016/j.clinbiochem.2011.11.016Search in Google Scholar PubMed
77. Ham M, Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharm Res 2013;36:1419–31.10.1007/s12272-013-0271-7Search in Google Scholar PubMed
78. Huang J, Ang L, Liu MQ, Hu HG, Wang J, Zou Q, Zhao Y, Zheng L, Zhao M, Wu ZS. Serum and tissue expression of gelatinase and Twist in breast cancer. Eur Rev Med Pharmacol Sci 2014;18:2662–9.Search in Google Scholar
79. Puzovic V, Brcic I, Ranogajec I, Jakic-Razumovic J. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients. Neoplasma 2014;61:439–46.10.4149/neo_2014_054Search in Google Scholar PubMed
80. Kim GE, Lee JS, Choi YD, Lee KH, Lee JH, Nam JH, Choi C, Kim SS, Park MH, Yoon JH, Kweon SS. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer 2014;14:959.10.1186/1471-2407-14-959Search in Google Scholar PubMed PubMed Central
81. Noh H, Hong S, Huang S. Role of urokinase receptor in tumor progression and development. Theranostics 2013;3:487–95.10.7150/thno.4218Search in Google Scholar PubMed PubMed Central
82. Tang L, Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 2013;67:179–82.10.1016/j.biopha.2012.10.003Search in Google Scholar PubMed
83. Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). Expert Opin Ther Pat 2013;23:801–15.10.1517/13543776.2013.782393Search in Google Scholar PubMed
84. Cancello R, Rouault C, Guilhem G, Bedel JF, Poitou C, Di Blasio AM, Basdevant A, Tordjman J, Clément K. Urokinase plasminogen activator receptor in adipose tissue macrophages of morbidly obese subjects. Obes Facts 2011;4:17–25.10.1159/000324587Search in Google Scholar PubMed PubMed Central
85. Heraclides A, Jensen TM, Rasmussen SS, Eugen-Olsen J, Haugaard SB, Borch-Johnsen K, Sandbæk A, Lauritzen T, Witte DR. The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia 2013;56:1542–6.10.1007/s00125-013-2914-0Search in Google Scholar PubMed
86. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012;92:635–88.10.1152/physrev.00008.2011Search in Google Scholar PubMed PubMed Central
87. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2010;29:295–307.10.1007/s10555-010-9221-8Search in Google Scholar PubMed
88. Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol 2015;26:95–100.10.1093/annonc/mdu487Search in Google Scholar PubMed
89. Azim HA Jr, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart M, Michiels S, Sotiriou C. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS One 2013;8:e62451.10.1371/journal.pone.0062451Search in Google Scholar PubMed PubMed Central
90. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM, Soares FA. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011;126:1–14.10.1007/s10549-010-0867-2Search in Google Scholar PubMed
91. Botti G, Scognamiglio G, Marra L, Collina F, Di Bonito M, Cerrone M, Grilli B, Anniciello A, Franco R, Fulciniti F, Ascierto PA, Cantile M. SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. Virchows Arch 2014;465:331–8.10.1007/s00428-014-1616-4Search in Google Scholar PubMed
92. Girotti MR, Fernández M, López JA, Camafeita E, Fernández EA, Albar JP, Benedetti LG, Valacco MP, Brekken RA, Podhajcer OL, Llera AS. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. J Invest Dermatol 2011;131:2438–47.10.1038/jid.2011.239Search in Google Scholar PubMed
93. Shin M, Mizokami A, Kim J, Ofude M, Konaka H, Kadono Y, Kitagawa Y, Miwa S, Kumaki M, Keller ET, Namiki M. Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. Prostate 2013;73:1159–70.10.1002/pros.22664Search in Google Scholar PubMed
94. Horiguchi H, Yamagata S, Rong Qian Z, Kagawa S, Sakashita N. Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis. J Med Invest 2013;60:91–6.10.2152/jmi.60.91Search in Google Scholar PubMed
95. Ioachim E, Damala K, Tsanou E, Briasoulis E, Papadiotis E, Mitselou A, Charhanti A, Doukas M, Lampri L, Arvanitis DL. Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. Histol Histopathol 2012;27:209–16.Search in Google Scholar
96. Suh EJ, Kabir MH, Kang UB, Lee JW, Yu J, Noh DY, Lee C. Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. Exp Mol Med 2012;44:36–44.10.3858/emm.2012.44.1.003Search in Google Scholar PubMed PubMed Central
97. Miyata Y, Mitsunari K, Asai A, Takehara K, Mochizuki Y, Sakai H. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy. Prostate 2015;75:84–91.10.1002/pros.22894Search in Google Scholar PubMed PubMed Central
98. Lee SH, Lee JA, Park HS, Song YS, Jang YJ, Kim JH, Lee YJ, Heo Y. Associations among SPARC mRNA expression in adipose tissue, serum SPARC concentration and metabolic parameters in Korean women. Obesity (Silver Spring) 2013;21:2296–302.10.1002/oby.20183Search in Google Scholar PubMed
99. Wu D, Li L, Yang M, Liu H, Yang G. Elevated plasma levels of SPARC in patients with newly diagnosed type 2 diabetes mellitus. Eur J Endocrinol 2011;165:597–601.10.1530/EJE-11-0131Search in Google Scholar PubMed
100. Kos K, Wong S, Tan B, Gummesson A, Jernas M, Franck N, Kerrigan D, Nystrom FH, Carlsson LM, Randeva HS, Pinkney JH, Wilding JP. Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. Diabetes 2009;58:1780–8.10.2337/db09-0211Search in Google Scholar PubMed PubMed Central
101. Kotani K, Yamada T, Taniguchi N. The association between circulating secreted protein acidic and rich in cysteine (SPARC) and glycosylated haemoglobin (HbA(1c)) during lifestyle-modified weight reduction intervention in obese male subjects. J Int Med Res 2011;39:528–32.10.1177/147323001103900221Search in Google Scholar PubMed
102. Chavey C, Boucher J, Monthouël-Kartmann MN, Sage EH, Castan-Laurell I, Valet P, Tartare-Deckert S, Van Obberghen E. Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia. Obesity (Silver Spring) 2006;14:1890–7.10.1038/oby.2006.220Search in Google Scholar PubMed
103. Shen Y, Zhao Y, Yuan L, Yi W, Zhao R, Yi Q, Yong T. SPARC is over-expressed in adipose tissues of diet-induced obese rats and causes insulin resistance in 3T3-L1 adipocytes. Acta Histochem 2014;116:158–66.10.1016/j.acthis.2013.06.004Search in Google Scholar PubMed
104. Varma V, Yao-Borengasser A, Bodles AM, Rasouli N, Phanavanh B, Nolen GT, Kern EM, Nagarajan R, Spencer HJ 3rd, Lee MJ, Fried SK, McGehee RE Jr,Peterson CA, Kern PA. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008;57:432–9.10.2337/db07-0840Search in Google Scholar PubMed PubMed Central
105. Kong P, Cavalera M, Frangogiannis NG. The role of thrombospondin (TSP)-1 in obesity and diabetes. Adipocyte 2014;3:81–4.10.4161/adip.26990Search in Google Scholar PubMed PubMed Central
106. Chavez RJ, Haney RM, Cuadra RH, Ganguly R, Adapala RK, Thodeti CK, Raman P. Upregulation of thrombospondin-1 expression by leptin in vascular smooth muscle cells via JAK2- and MAPK-dependent pathways. Am J Physiol Cell Physiol 2012;303:C179–91.10.1152/ajpcell.00008.2012Search in Google Scholar PubMed
107. Cui W, Maimaitiyiming H, Qi X, Norman H, Wang S. Thrombospondin 1 mediates renal dysfunction in a mouse model of high-fat diet-induced obesity. Am J Physiol Renal Physiol 2013;305:F871–80.10.1152/ajprenal.00209.2013Search in Google Scholar PubMed PubMed Central
108. Garcia-Diaz DF, Arellano AV, Milagro FI, Moreno-Aliaga MJ, Portillo MP, Martinez JA, Campion J. Glucose and insulin modify thrombospondin 1 expression and secretion in primary adipocytes from diet-induced obese rats. J Physiol Biochem 2011;67:453–61.10.1007/s13105-011-0081-7Search in Google Scholar PubMed
109. Inoue M, Jiang Y, Barnes RH 2nd, Tokunaga M, Martinez-Santibañez G, Geletka L, Lumeng CN, Buchner DA, Chun TH. Thrombospondin 1 mediates high-fat diet-induced muscle fibrosis and insulin resistance in male mice. Endocrinology 2013;154:4548–59.10.1210/en.2013-1587Search in Google Scholar PubMed PubMed Central
110. Kong P, Gonzalez-Quesada C, Li N, Cavalera M, Lee DW, Frangogiannis NG. Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation. Am J Physiol Endocrinol Metab 2013;305:E439–50.10.1152/ajpendo.00006.2013Search in Google Scholar PubMed PubMed Central
111. You JJ, Yang CH, Chen MS, Yang CM. Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2009;50:3447–55.10.1167/iovs.08-2603Search in Google Scholar PubMed
112. Hughes JM, Kuiper EJ, Klaassen I, Canning P, Stitt AW, Van Bezu J, Schalkwijk CG, Van Noorden CJ, Schlingemann RO. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia 2007;50:1089–98.10.1007/s00125-007-0621-4Search in Google Scholar PubMed PubMed Central
113. Bouchard L, Tchernof A, Deshaies Y, Lebel S, Hould FS, Marceau P, Vohl MC. CYR61 polymorphisms are associated with plasma HDL-cholesterol levels in obese individuals. Clin Genet 2007;72:224–9.10.1111/j.1399-0004.2007.00855.xSearch in Google Scholar PubMed
114. Tan JT, McLennan SV, Williams PF, Rezaeizadeh A, Lo LW, Bonner JG, Twigg SM. Connective tissue growth factor/CCN-2 is upregulated in epididymal and subcutaneous fat depots in a dietary-induced obesity model. Am J Physiol Endocrinol Metab 2013;304:E1291–302.10.1152/ajpendo.00654.2012Search in Google Scholar PubMed
115. Mason RM. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal 2009;3:95–104.10.1007/s12079-009-0038-6Search in Google Scholar
116. McLennan SV, Abdollahi M, Twigg SM. Connective tissue growth factor, matrix regulation, and diabetic kidney disease. Curr Opin Nephrol Hypertens 2013;22:85–92.10.1097/MNH.0b013e32835b4889Search in Google Scholar PubMed
117. Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Höppener JW, Goldschmeding R. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006;290:F1344–54.10.1152/ajprenal.00174.2005Search in Google Scholar PubMed
118. Van Geest RJ, Leeuwis JW, Dendooven A, Pfister F, Bosch K, Hoeben KA, Vogels IM, Van der Giezen DM, Dietrich N, Hammes HP, Goldschmeding R, Klaassen I, Van Noorden CJ, Schlingemann RO. Connective tissue growth factor is involved in structural retinal vascular changes in long-term experimental diabetes. J Histochem Cytochem 2014;62:109–18.10.1369/0022155413512656Search in Google Scholar PubMed PubMed Central
119. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738–44.10.1053/jhep.2001.28055Search in Google Scholar PubMed
120. Lee CI, Guh JY, Chen HC, Lin KH, Yang YL, Hung WC, Lai YH, Chuang LY. Leptin and connective tissue growth factor in advanced glycation end-product-induced effects in NRK-49F cells. J Cell Biochem 2004;93:940–50.10.1002/jcb.20222Search in Google Scholar PubMed
121. Martínez-Martínez E, Miana M, Jurado-López R, Bartolomé MV, Souza Neto FV, Salaices M, López-Andrés N, Cachofeiro V. The potential role of leptin in the vascular remodeling associated with obesity. Int J Obes (Lond) 2014;38:1565–72.10.1038/ijo.2014.37Search in Google Scholar PubMed
122. Pakradouni J, Le Goff W, Calmel C, Antoine B, Villard E, Frisdal E, Abifadel M, Tordjman J, Poitou C, Bonnefont-Rousselot D, Bittar R, Bruckert E, Clément K, Fève B, Martinerie C, Guérin M. Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders. PLoS One 2013;8:e66788.10.1371/journal.pone.0066788Search in Google Scholar PubMed PubMed Central
123. Murahovschi V, Pivovarova O, Ilkavets I, Dmitrieva RM, Döcke S, Keyhani-Nejad F, Gögebakan O, Osterhoff M, Kemper M, Hornemann S, Markova M,Klöting N, Stockmann M, Weickert MO, Lamounier-Zepter V, Neuhaus P, Konradi A, Dooley S, von Loeffelholz C, Blüher M, Pfeiffer AF, Rudovich N. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes 2015;64:856–66.10.2337/db14-0444Search in Google Scholar PubMed
124. Dahlman I, Elsen M, Tennagels N, Korn M, Brockmann B, Sell H, Eckel J, Arner P. Functional annotation of the human fat cell secretome. Arch Physiol Biochem 2012;118:84–91.10.3109/13813455.2012.685745Search in Google Scholar PubMed
125. Hammarstedt A, Hedjazifar S, Jenndahl L, Gogg S, Grünberg J, Gustafson B, Klimcakova E, Stich V, Langin D, Laakso M, Smith U. WISP2 regulates preadipocyte commitment and PPARγ activation by BMP4. Proc Natl Acad Sci USA 2013;110:2563–8.10.1073/pnas.1211255110Search in Google Scholar PubMed PubMed Central
126. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2-an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010;118:4–8.10.1055/s-0029-1243193Search in Google Scholar PubMed
127. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 2014;14:329–41.10.1038/nrc3720Search in Google Scholar PubMed
128. Russo VC, Azar WJ, Yau SW, Sabin MA, Werther GA. IGFBP-2: The dark horse in metabolism and cancer. Cytokine Growth Factor Rev (Online 2014 Dec 18; PubMed ID: 25544066; doi: 10.1016/j.cytogfr.2014.12.001; pii: S1359-6101(14)00165-8).Search in Google Scholar
129. Holbourn KP, Acharya KR, Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci 2008;33:461–73.10.1016/j.tibs.2008.07.006Search in Google Scholar PubMed PubMed Central
130. Dhar A, Ray A. The CCN family proteins in carcinogenesis. Exp Oncol 2010;32:2–9.Search in Google Scholar
131. Tomita N, Hattori T, Itoh S, Aoyama E, Yao M, Yamashiro T, Takigawa M. Cartilage-specific over-expression of CCN family member 2/connective tissue growth factor (CCN2/CTGF) stimulates insulin-like growth factor expression and bone growth. PLoS One 2013;8:e59226.10.1371/journal.pone.0059226Search in Google Scholar PubMed PubMed Central
132. Cui RR, Huang J, Yi L, Xie H, Zhou HD, Yuan LQ, Wang M, Peng YQ, Luo XH, Liao EY. WISP3 suppresses insulin-like growth factor signaling in human chondrocytes. Mol Cell Endocrinol 2007;279:1–8.10.1016/j.mce.2007.08.007Search in Google Scholar PubMed
133. Repudi SR, Patra M, Sen M. WISP3-IGF1 interaction regulates chondrocyte hypertrophy. J Cell Sci 2013;126:1650–8.Search in Google Scholar
134. Sureshbabu A, Tonner E, Flint DJ. Insulin-like growth factor binding proteins and mammary gland development. Int J Dev Biol 2011;55:781–9.10.1387/ijdb.113364asSearch in Google Scholar PubMed
135. Lorenzatti G, Huang W, Pal A, Cabanillas AM, Kleer CG. CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer. J Cell Sci 2011;124(Pt 10):1752–8.10.1242/jcs.084194Search in Google Scholar PubMed PubMed Central
136. Zhang Y, Pan Q, Zhong H, Merajver SD, Kleer CG. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res. 2005;7:R1080–9.10.1186/bcr1351Search in Google Scholar PubMed PubMed Central
137. Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011;10:945–63.10.1038/nrd3599Search in Google Scholar PubMed PubMed Central
138. Zhang C, Luo X, Liu L, Guo S, Zhao W, Mu A, Liu Z, Wang N, Zhou H, Zhang T. Myocardin-related transcription factor A is up-regulated by 17β-estradiol and promotes migration of MCF-7 breast cancer cells via transactivation of MYL9 and CYR61. Acta Biochim Biophys Sin 2013;45:921–7.10.1093/abbs/gmt104Search in Google Scholar PubMed
139. Sampath D, Winneker RC, Zhang Z. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology 2001;142:2540–8.10.1210/endo.142.6.8186Search in Google Scholar PubMed
140. Chien W, O’Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, Vadgama J, Lyons KM, Koeffler HP. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol 2011;38:1741–7.10.3892/ijo.2011.985Search in Google Scholar PubMed PubMed Central
141. Ohgawara T, Kubota S, Kawaki H, Kurio N, Abd El Kader T, Hoshijima M, Janune D, Shimo T, Perbal B, Sasaki A, Takigawa M. Association of the metastatic phenotype with CCN family members among breast and oral cancer cells. J Cell Commun Signal 2011;5:291–9.10.1007/s12079-011-0133-3Search in Google Scholar PubMed PubMed Central
142. Davies SR, Watkins G, Mansel RE, Jiang WG. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol 2007;14:1909–18.10.1245/s10434-007-9376-xSearch in Google Scholar PubMed
143. Klinke DJ 2nd. Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput Biol 2014;10:e1003409.10.1371/journal.pcbi.1003409Search in Google Scholar PubMed PubMed Central
144. Kouzu Y, Uzawa K, Kato M, Higo M, Nimura Y, Harada K, Numata T, Seki N, Sato M, Tanzawa H. WISP-2 expression in human salivary gland tumors. Int J Mol Med 2006;17:567–73.10.3892/ijmm.17.4.567Search in Google Scholar
145. Sabbah M, Prunier C, Ferrand N, Megalophonos V, Lambein K, De Wever O, Nazaret N, Lachuer J, Dumont S, Redeuilh G. CCN5, a novel transcriptional repressor of the transforming growth factor β signaling pathway. Mol Cell Biol 2011;31:1459–69.10.1128/MCB.01316-10Search in Google Scholar PubMed PubMed Central
146. Ferrand N, Stragier E, Redeuilh G, Sabbah M. Glucocorticoids induce CCN5/WISP-2 expression and attenuate invasion in oestrogen receptor-negative human breast cancer cells. Biochem J 2012;447:71–9.10.1042/BJ20120311Search in Google Scholar PubMed
147. Inadera H, Hashimoto S, Dong HY, Suzuki T, Nagai S, Yamashita T, Toyoda N, Matsushima K. WISP-2 as a novel estrogen-responsive gene in human breast cancer cells. Biochem Biophys Res Commun 2000;275:108–14.10.1006/bbrc.2000.3276Search in Google Scholar PubMed
148. Fritah A, Redeuilh G, Sabbah M. Molecular cloning and characterization of the human WISP-2/CCN5 gene promoter reveal its upregulation by oestrogens. J Endocrinol 2006;191:613–24.10.1677/joe.1.07009Search in Google Scholar PubMed
149. Haque I, Banerjee S, Dhar K, Ray A, Banerjee SK. CCN5/WISP-2 prevents leptin-induced breast tumor cell growth and migration [abstract]. Proceedings of Cancer Research Symposium, University of Kansas Cancer Center 2009;15.Search in Google Scholar
150. Huang W, Pal A, Kleer CG. On how CCN6 suppresses breast cancer growth and invasion. J Cell Commun Signal 2012;6:5–10.10.1007/s12079-011-0148-9Search in Google Scholar PubMed PubMed Central
151. Leask A. CCN6: a novel method of aTAKing cancer. J Cell Commun Signal 2013;7:161–2.10.1007/s12079-012-0189-8Search in Google Scholar PubMed PubMed Central
©2015 by De Gruyter